Developments include positive clinical results for an mRNA vaccine, a major design partnership between Google and Marvell, and macroeconomic shifts regarding currency and Bitcoin.

The entities involved

• Moderna →

  American biotechnology company

  • Analyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Mon 17:09
  • Positive test results were reported for Moderna's flu vaccine.Sun 15:33
• Google →

  American multinational technology company, a subsidiary of Alphabet Inc.

  • Google referrals for publishers declined by 36%, according to Chartbeat data.Mon 17:38
  • A global center for quantum research is located in Goleta.Mon 16:53
• U.S. Treasury →

  mine in Sierra County, New Mexico, United States of America

  • Renewed U.S.-Iran tensions are discussed at a G20 gathering, adding inflation pressure to global yields.Mon 15:26
  • Market instability mounts as rising yields above 5.2% weaken demand, higher oil prices affect jet fuel costs, and Meta announces its personal AI agent Muse.Mon 12:50

Related events

• Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.Aug 25
• Google gained permission to buy a $12B stake, coinciding with positive late-stage trial results for a cancer vaccine.Aug 19
• Berkshire Hathaway and Warren Buffett commented on the Moderna and Merck partnership, criticizing market speculation while noting positive news regarding the mRNA vaccine collaboration.Aug 28
• GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.Jun 7
• On August 28, 2026, the FDA approved Moderna's mNEXSPIKE vaccine and gave the green light to Novavax's Nuvaxovid vaccine. Separately, ProFound Therapeutics was formed by Flagship Pioneering.Aug 28